Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013

Anna Asklid^{1

2}, Maria Winqvist^{1

3}, Sandra Eketorp Sylvan¹, Agnes Mattsson^{1

4}, Einar Björgvinsson^{1

2}, Frans Søltoft⁵, Johanna Repits⁶, Joris Diels⁷, Anders Österborg^{1

3}, Lotta Hansson^{1

3}

Affiliations

¹ a Department of Oncology-Pathology , Karolinska Institutet , Stockholm , Sweden.
² b Department of Oncology , Karolinska University Hospital , Stockholm , Sweden.
³ d Department of Hematology , Karolinska University Hospital Solna , Stockholm , Sweden.
⁴ c Department of Internal Medicine , Södersjukhuset , Stockholm , Sweden.
⁵ e Janssen Nordic , Birkerød , Denmark.
⁶ f Previously at Janssen Nordic , Stockholm , Sweden.
⁷ g Janssen EMEA , Antwerp , Belgium.

Anna Asklid et al. Leuk Lymphoma. 2017 May.

. 2017 May;58(5):1219-1223.

doi: 10.1080/10428194.2016.1246727. Epub 2016 Nov 28.

¹ a Department of Oncology-Pathology , Karolinska Institutet , Stockholm , Sweden.
² b Department of Oncology , Karolinska University Hospital , Stockholm , Sweden.
³ d Department of Hematology , Karolinska University Hospital Solna , Stockholm , Sweden.
⁴ c Department of Internal Medicine , Södersjukhuset , Stockholm , Sweden.
⁵ e Janssen Nordic , Birkerød , Denmark.
⁶ f Previously at Janssen Nordic , Stockholm , Sweden.
⁷ g Janssen EMEA , Antwerp , Belgium.

No abstract available

Publication types